HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.7%

Neg 0% Neu 91.7% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.